Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
80M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
35.2M
-
Shares change
-
+207K
-
Total reported value, excl. options
-
$744M
-
Value change
-
+$3.82M
-
Number of buys
-
35
-
Number of sells
-
-47
-
Price
-
$21.15
Significant Holders of Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) as of Q4 2021
111 filings reported holding AKRO - Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.2M shares
of 80M outstanding shares and own 44% of the company stock.
Largest 10 shareholders include Skorpios Trust (4.91M shares), JANUS HENDERSON GROUP PLC (3.16M shares), ALKEON CAPITAL MANAGEMENT LLC (2.48M shares), Atlas Venture Life Science Advisors, LLC (2.23M shares), venBio Partners LLC (2.17M shares), BlackRock Inc. (1.94M shares), WELLINGTON MANAGEMENT GROUP LLP (1.88M shares), GOLDMAN SACHS GROUP INC (1.77M shares), Point72 Asset Management, L.P. (1.76M shares), and Redmile Group, LLC (1.6M shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.